TrialJournal for immunotherapy of cancer2026

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Mohamed H Derbala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.